- News & Events
- Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable Human Papillomavirus 16-related cancer
Encouraging results from a synthetic vaccine
Key points of this study:
Question: Is the efficacy of programmed cell death 1 immune checkpoint inhibition increased by a tumor-specific vaccine in patients with incurable human papillomavirus 16-positive cancer?
Findings: In the phase 2 clinical trail of nivolumab and human papillomavirus 16 vaccine ISA101, the primary end point was met, with a 33% overall response rate (8 of 24 patients), compared with response rates of 16% to 22% with programmed cell death 1 inhibitors alone in similar patients. Survival data were also encouraging, with a median survival of 17.5 months.
Meaning: These data indicate that HPV-16 vaccination may augment the efficacy of programmed cell death 1 checkpoint inhibition and merit confirmation in a randomized trial.
Full details of this Phase 2 Clinical Trial available here.
View other News Articles